Cancer Immunotherapy with Immune Checkpoint Inhibitors-Biomarkers of Response and Toxicity; Current Limitations and Future Promise
Immune checkpoint inhibitors are monoclonal 330 gph filter pump antibodies that are used to treat over one in three cancer patients.While they have changed the natural history of disease, prolonging life and preserving quality of life, they are highly active in less than 40% of patients, even in the most responsive malignancies such as melanoma, an